Connect with us

Uncategorized

American Green Inc (OTCMKTS: ERBB) Major 2nd Leg Brewing as Co Closes Lease on 35,000 SF Facility

Published

on

American Green Inc (OTCMKTS: ERBB) is making another powerhouse move up the charts towards the $0.023 a level once surpassed will propel ERBB into a whole new trading range after the Company announced it has signed a lease with an option to buy a 35,100 square foot building located in Phoenix, Arizona, and is expected to generate $10 million in annual revenue when fully operational.  The additional revenue is approximately 500% more annual revenue than American Green’s current $2 million annual revenue.  The new facility will house a state-of-the-art kitchen for the manufacture of premium edible and concentrate cannabis products. Interior design will incorporate a two-tiered layout designed to maximize revenue as well as square footage. 

ERBB took off late last year out of sub penny land and has skyrocketed to recent highs of $0.023 per share. As long-term penny stock speculators know ERBB has a long history of highly explosive moves and with a shareholder base exceeding 50,000 stockholders of record ERBB should be at the top of most speculators watch lists. Currently under heavy accumulation ERBB is moving steadily northbound with many new investors buying in every day. ERBB is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.023 and its blue skies ahead. 

American Green Inc (OTCMKTS: ERBB) is among the original pot stocks starting back in 2009 the Company became America’s second publicly-traded company in the cannabis sector. American Green now, with its more than 50,000 certified beneficial shareholders, is one of the largest (in shareholder count) in the cannabis sector.  American Green’s mission is to lead the cannabis and premium CBD industry. Leveraging its team of professionals in cultivation management, manufacturing, extraction, wholesale, retail, and community outreach, strives to develop sustainable initiatives in the cannabis-adjacent and CBD industries, laser-focused on adding company and shareholder value. 

The Company operates out of a 12,000 sq ft modern and very efficient grow facility in West Phonix, Arizona where they have invested around $3 million. Recently American Green won a lawsuit against the building owners who were trying to incrase the rent.  

The stock took off last year after the Company announced for the six-month period ending December 31, 2020, it has reached all-time highs in sales and gross profits. The Company’s cannabis grow management operation in Phoenix, called “Sweet Virginia,” delivered a record $892,265 in revenue compared to the same six-month period in 2019 of $773,079. Along with this revenue growth, the grow management operation booked gross profits of $636,848 compared to $511,510 in the same period of the previous year.  Its revenues and gross profits were 15% and 24% higher than the same periods in the previous year. 

Company president David Gwyther said, “I am extremely pleased that we booked these record numbers. Our team put in an amazing effort last year during very trying times and for us to report our best numbers ever is a credit to them and to the people who believe in our company and products. Our online CBD division also hit record sales numbers for the same six-month period ending December 31, 2020. Revenue was up 10% and profitability was up a significant 41% as a result of greater overall efficiencies and bulk purchasing power.  American Green continues to gain momentum with the American Green Online Emporium and is very pleased with the sales of selected American Green products offered through Amazon which began a few months ago. Look for additional Hemp products to be released for sale on Amazon in March and in the coming months. A great number of Cannabis and CBD opportunities have opened up for American Green in Arizona – our home state – and throughout the United States. We plan to take full advantage of these expansion opportunities appearing right in front of us. This will allow for continued record-setting revenues and gross profits.   We are looking forward to a great year for American Green and our shareholders,” concluded Mr. Gwyther. 

https://twitter.com/homecashworks/status/1372527217071157248

To Find out the inside Scoop on ERBB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ERBB

Earlier this month ERBB announced it has been selling the majority of its Premium Cannabis grown at its “Sweet Virginia” Grow operation to Venom Extracts — a Curaleaf Holdings, Inc. licensee. Over the past year, American Green has been working with and developing a great relationship with Venom Extracts.  

American Green started out selling its premium cannabis on the wholesale market. However, as time went on the Company identified a need for premium quality fresh-frozen cannabis, used for producing top quality concentrate products. Currently, American Green-grown premium cannabis products are available to quality-minded customers in more than 50 dispensaries under various high-end cannabis brands throughout Arizona.   Venom has been purchasing a large majority of American Green’s harvests and using the product to create a variety of Live Resin offerings. They are extracting the terpenes from our premium cannabis and using them in many of the Select** Brand concentrate products. Venom is also producing THCA diamonds using American Green’s premium cannabis. 

On May 6 ERBB announced it has signed a lease with an option to buy a 35,100 square foot building located in Phoenix, Arizona, and is expected to generate $10 million in annual revenue when fully operational.  The additional revenue is approximately 500% more annual revenue than American Green’s current $2 million annual revenue.  The new facility will house a state-of-the-art kitchen for the manufacture of premium edible and concentrate cannabis products. Interior design will incorporate a two-tiered layout designed to maximize revenue as well as square footage. 

American Green’s lease starts with an initial 5 years and includes an option for renewal for three more 5-year terms along with an option to purchase the building within 2 years of the lease start date.  This is the second cannabis operation for ERBB in its home state of Arizona. The new location is just a few miles from its current “Sweet Virginia” Grow Facility.  The new building is zoned “Commercial A-1” which is the appropriate zone to operate as a Cannabis Grow, subject to approval from the City of Phoenix.  American Green plans to employ approximately 35 people for the new development. 

The American Green laboratory will be producing top-tier concentrate offerings within its first year of operation. Medical and recreational users can look forward to what has already been established as the 2nd most desired cannabis product, “Live Resin,” “Diamonds and Sauce,” “Budder,” and “Applesauce” consistencies – each one of them produced using American Green’s proprietary in-house grown selection of cannabis genetics. 

As a follow up to an earlier news, Chef Dee Russell A.K.A. “Edible Dee” and “The Happy Chef” will be instrumental in the design of the kitchen, equipment purchases, and American Green’s premium edible and concentrate recipes. American Green will use Gierczyk Inc. for the design-build construction of the new facility. 

David G. Gwyther, American Green’s president, commented, “Utilizing every square foot of space strategically and efficiently will be a priority for us as we build out our newest facility. Our prime goal will be to create a state-of-the-art facility designed to exceed our estimate of adding $10 million a year in annual corporate revenues.” 

 

For More on ERBB Subscribe Right Now!

American Green Inc (OTCMKTS: ERBB) is making another powerhouse move up the charts towards the $0.023 a level once surpassed will propel ERBB into a whole new trading range after the Company announced it has signed a lease with an option to buy a 35,100 square foot building located in Phoenix, Arizona, and is expected to generate $10 million in annual revenue when fully operational.  The additional revenue is approximately 500% more annual revenue than American Green’s current $2 million annual revenue.  The new facility will house a state-of-the-art kitchen for the manufacture of premium edible and concentrate cannabis products. Interior design will incorporate a two-tiered layout designed to maximize revenue as well as square footage.  ERBB took off late last year out of sub penny land and has skyrocketed to recent highs of $0.023 per share. As long-term penny stock speculators know ERBB has a long history of highly explosive moves and with a shareholder base exceeding 50,000 stockholders of record ERBB should be at the top of most speculators watch lists. Currently under heavy accumulation ERBB is moving steadily northbound with many new investors buying in every day. ERBB is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.023 and its blue skies ahead. We will be updating on ERBB on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with ERBB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ERBB either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis

Published

on

Clean Vision Corporation (OTC: CLNV) has experienced several interesting developments recently, but it hasn’t noticeably influenced the market with any substantial gains. Nonetheless, we believe it’s worth providing an update on the company given it’s been a few months since our last mention. In today’s discussion, we’ll explore a variety of updates and their significance, with aim of providing insight on what to expect for 2024.

Background:

Clean Vision is led by Dan Bates, and their goal is to tackle the global plastic waste crisis head-on. Their wholly owned subsidiary, Clean Seas, has developed the Plastic Conversion Network (PCN), a groundbreaking technology aimed at diverting millions of tons of waste plastic from landfills, incineration, and oceans. The PCN converts this plastic feedstock into clean fuels and green hydrogen, significantly reducing reliance on fossil fuels and lowering the carbon footprint.

For a brief 2 minute overview on the company, feel free to reference the video CLNV’s subsidiary put together on YouTube. Here’s the link.

Clean Seas utilizes proven pyrolysis technology to produce environmentally friendly products, which are sold to multinational petrochemical companies, driving the circular plastic economy. Operational PCN facilities are already in place in Morocco and India, with additional conversion facilities in development across West Virginia, Arizona, and Southeast Asia. Long-term feedstock supply agreements exceeding one million tons of waste plastic annually have been secured at no cost.

Their recently trademarked brand, AquaH®, is produced in their PCN. According to the release, it offers a differentiated green hydrogen product from carbon-neutral sources. Currently, hydrogen is predominantly produced through methods that involve fossil fuels, which of course contributes to global carbon emissions. Furthermore according to Deloitte’s 2023 global green hydrogen outlook, this could be a $1.4T annual market by 2050.

$65 Million Plastic Conversion Facility:

CLNV is making big moves in West Virginia and according to the release on October 24th, 2023, they’ve brought in some serious players—CDI Engineering Solutions and ERM—to help out with their Clean-Seas West Virginia project.

CDI has over 70 years of experience integrating engineering, design, project support, procurement and construction management services to the energy, chemicals and electrical infrastructure markets.

ERM is the world’s largest advisory firm focused solely on sustainability, offering environmental, health, safety, risk and social expertise for more than 50 years with more than 8,500 dedicated professionals operating across 40 countries.

The plan is to kick things off in 2024, turning 100 tons of plastic every day into recycled plastics and clean fuels. It’s a hefty project with a $65 million investment, creating over 200 jobs initially. And they’re not stopping there—they want to scale up to 500 tons of plastic per day over time.

West Virginia Governor Jim Justice is also on board, throwing over $12 million in state incentives to support the project.

Governor Jim Justice made a reference to Clean Seas in his state of the union address. If you want to catch the mention, go to 34:15 in the video. The three minutes leading up to it are also worth reviewing.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Launches Global Operations:

CLNV made another significant advancement, planning to launch waste plastic conversion facilities in the European Union, Eastern Europe, and Southeast Asia. This will be accomplished through their new subsidiary, Clean-Seas Partners UK Limited (CS-UK), who of course shares the same vision of creating sustainable solutions to the global plastic pollution crisis.

Under the leadership of Managing Director Shaun Wootton, CS-UK will play a crucial role in strategic project development and investment facilitation, leveraging established relationships in the Middle East, Southeast Asia, and Europe.

To fortify effective governance and strategic direction, CS-UK is assembling a distinguished board with internationally recognized figures in banking, sustainability, and energy. This approach aims to have a diverse and experienced board guiding CS-UK in realizing its vision of promoting sustainability and environmental stewardship across diverse regions.

$340 Million Bond Offering:

CLNV even announced they partnered with a global advisory firm, Grant Thornton, to issue up to $340 million in Green Bonds. This is the world’s sixth-largest network of independent accounting and consulting firms, employing 62,000 people in more than 130 countries and had revenues of $6.6 billion in 2021. These bonds will fund the expansion of Clean Vision’s Plastic Conversion Network (PCN) under the “Clean-Seas” initiative worldwide, aimed at combatting plastic pollution on a global scale.

With the Green Bond’s net proceeds, CLNV plans to deploy at least six plastic waste conversion lines globally, with strategic locations in West Virginia, Arizona, Southeast Asia, and expansion in Morocco. The Green Bond is also expected to attract environmentally conscious investors, setting a new standard for corporate responsibility.

$15M Government Loan:

Lastly, under the capable management of Huntington Bank, CLNV has recently secured a $15 million government loan. What sets this apart is that the loan is FORGIVABLE.

A forgivable loan is a type of loan where the borrower is not required to repay the borrowed amount under certain conditions. Typically, these conditions are related to the borrower meeting specific criteria, such as using the funds for approved purposes, maintaining certain employment levels, or achieving predetermined goals. If the borrower fulfills these conditions, the loan is forgiven, and they are not obligated to repay the borrowed amount. Forgivable loans are often used as an incentive or support for specific activities, such as job creation, small business development, or other initiatives that contribute to economic growth or community welfare.

Not to mention it won’t result in any dilution for shareholders. This is an unexpected and uncommon accomplishment for an OTC company. Securing a government loan of this size without any dilution is truly impressive.

Conclusion:

CLNV has made impressive strides tackling the global plastic waste crisis, especially given their valuation of merely $22.65 million. The team has swiftly achieved key objectives, including a $65 million plastic conversion facility in West Virginia, global expansion through Clean-Seas Partners UK Limited, a $340 million Green Bond Offering, and a remarkable $15 million forgivable government loan. The vast $1.4 trillion market they’re tapping into offers an interesting opportunity with current indicators looking positive. Nevertheless, it’s crucial to acknowledge that there is still significant work ahead, and the team needs to maintain consistent execution to turn this potential into a reality.

We will update you on CLNV when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by pasja1000 from Pixabay

Continue Reading

Featured

Integrated Cannabis Solutions’ (OTC: IGPK) 633% Surge: Exploring Catalysts, Company Overview, and Growth Potential in 2024

Published

on

Integrated Cannabis Solutions (OTC: IGPK) has undergone a remarkable uptrend, surging an impressive 633% since December 11th, 2023, with 166% of that surge taking place across yesterday’s trading session and today, January 11th, 2023. Both days have been marked by unprecedented volume – Yahoo Finance reported an almost 30x increase, with 115,867,027 shares traded by close yesterday. We’re already seeing 90,092,317 shares traded this morning and it’s just barely noon. Today we’ll explore the catalysts behind the surge, offer a comprehensive overview of the company, and evaluate IGPK’s potential for sustained growth throughout 2024.

Background:

Let’s get straight to it. IGPK is the result of a recent reverse merger with Integrated Cannabis Solutions and JFH Digital E-Commerce Corp. The first thing you’ll notice is finding the website isn’t a walk in the park, we’re fairly certain there isn’t one yet, at least one that will help in any way related to more investment information. Your best bet for more any information is to check out IGPK’s OTC Market page for details, but even the company description on there is not accurate. We’ve mainly found the following information through filings, IGPK’s Twitter, and other online users.

Keep in mind this breakdown might not be flawless given we’re piecing it together mostly from what folks on X are saying. But we’ll try our absolute best to lay it all out for you.

IGPK appears to have been a shell for little while until JFH stepped in. A user on X, @stockplayer30, broke it down fairly simply, stating that the shell’s slate was wiped clean, cancelling all notes payable and any debt. Whether it’s a promissory note, convertible note, or convertible debenture, the main point is they ditched all debt. JFH has an opportunity to start fresh, and it certainly makes this deal a lot more interesting.

Just a heads up, it’s a Chinese merger. If the idea of a Chinese leadership team makes you a bit wary, you might want to pause here. However if you were in the trading game during the summer of ’23, you probably remember those crazy spikes in some Chinese Nasdaq deals. And get this – no big press releases or SEC filings to explain those sudden jumps either.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Company Description:

Onto what the company actually does. According to @SuperRobotOTC on X, this is a digital e-commerce company based in China, here’s a link to their e-commerce website. This user also put together a great overview of the company on YouTube, if you’d like to watch something informative in video format, click here.

Another user, @igal_n, found a blurb on the company that states, “Junfenghuang (JFH) is a digital asset. It is a token issued by Uplus Future Company with the help of blockchain technology. It has no direct relationship with the original equity”.

The Potential:

What makes this story extremely interesting is the sheer magnitude of how large JFH is, the intrinsic value does not appear to be valued accurately in the market, given it’s only freshly merged into IGPK’s tiny shell company on the OTC.

Their Gross Merchandise Value (GMV) is heading north of 50 billion yuan, and post-merger profits from service outlets are looking at a hefty 10 billion yuan – yes, billion with a B.

Steering the ship is a leadership team featuring President Wang Dejun, Treasurer Xie Weiji, and Director Yang Lanfang. With a whopping 750 subsidiaries, 250,000 merchants, and 30 million registered users. We’ve also heard from other sources that the registered users could be nearly double that, coming in at 50 million registered users.

These numbers are substantial for a company with a $7 million market cap. Looking ahead, it won’t be shocking if IGPK sets its sights on moving up to a bigger exchange like NASDAQ. It’s no secret they’re already in the big leagues – or it at least appears so. If that were the case, they’d of course have enhanced credibility, more visibility, and increased access to capital with institutional funding.

The App:

Now, you might be wondering, “Sounds cool, but it’s a Chinese merger with a whole setup on the other side of the planet. Can we trust this info?” @SuperRobotOTC has also gone the extra mile by downloading the app, and gave us the lowdown in video format. On top of the SEC filings, this is an added layer of trust & credibility we can attribute to this new venture. Here’s the link to the video.

Conclusion:

Fortunately it appears IGPK is still for the most part flying under the radar. There’s not even a proper website or accurate update on IGPK’s OTC Market overview to tell us what the company even entails. But here’s the silver lining – that might mean you’re still early. The intrinsic value of IGPK appears strongly disproportionate to its current value in the market.

Our advice? Keep a close eye on IGPK’s journey as it takes on this exciting phase of growth and exploration. It’s likely this story will catch wind quickly and it could be a great time to take advantage. As @SuperRobotOTC eluded to in his video, this could be the OTC’s largest merger, with a potential $70B valuation.

We will update you on IGPK when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by geralt from Pixabay

Continue Reading

Featured

Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A

Published

on

Orchard Therapeutics (NASDAQ: ORTX) experienced a remarkable 97% surge in its shares following a major announcement on October 5th, 2023. The renowned global gene therapy leader, Orchard, has been successfully acquired by Kyowa Kirin (OTC: KYKOF), solidifying its position as a fully owned subsidiary.

The Agreement:

The agreement outlines that Kyowa plans to buy all Orchard Therapeutics’ shares at $16.00 per share in cash (totalling about $387.4 million or around ¥57.3 billion) upon closure. This price is a 144% premium to Orchard’s previous value at close on October 4th, 2023.

As part of this deal, Orchard shareholders will receive an additional non-transferable CVR. Holders of the CVR will get a cash payout of $1.00 per share once OTL-200 for treating MLD in the U.S. gains approval.

For those that aren’t familiar, CVR stands for Contingent Value Right. It is a type of financial instrument or contractual right that entitles the holder to a payment or benefit if specific, predefined events or conditions are met. In the context of mergers or acquisitions, CVRs are often used as an additional incentive or compensation to shareholders based on the performance or success of certain agreed-upon benchmarks, such as the approval of a drug, achieving specific sales milestones, or reaching certain financial targets. The CVR allows shareholders to participate in the potential future success of a merged or acquired entity.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Predicting M&A in Advance:

Now that Orchard has been acquired, it’s probably not in your best interest to be trading it. What’s more important is being able to spot potential merger & acquisitions (M&A) before it happens. While it may seem like a large hurdle, enough research can put you in the right spot at the right time. And if you can do it well, there’s no question you’ll be increasing your earnings. Here’s 3 factors to think about when looking for potential M&A candidates.

1. Misvalued to the Extreme: Celgene’s Journey

Ever noticed how stock prices often have a mind of their own? Let’s talk about Celgene ($CELG), a big shot in the biotech world. Riding high with a super successful blood cancer drug called Revlimid, its stock price shot up from $25 to an incredible $139 between 2010 and 2017. Investors were all in.

But out of nowhere everything shifted. Worries about patents and competition suddenly tanked the stock to $60 within’ just 18 months – the stock had a massive swing in sentiment.

Did the once-celebrated star of the biotech world start hemorrhaging money? Was its revenue in a downward spiral? Far from it… In reality, 2018’s revenue saw only a minor dip from its peak in 2017, all the while the company was generating billions in profit.

Celgene gave it their all, teaming up with respected biotech experts, smart acquisitions of smaller companies with great prospective pipelines – even tried to engage Wall Street Critics, but nothing worked.

This twist in fortune caught the eye of Bristol Myers Squibb (NASDAQ:BMY), a company that values stability over trends. The lowered value of Celgene became a golden opportunity for them. They swooped in, acquiring Celgene, and securing promising assets. This stock market tale is a reminder that timing and how people perceive a situation can flip stock fortunes.

2. Great Science, but Lacking Funding:

Ever thought that a groundbreaking medicine should automatically become a hit? Turns out, it’s not that simple. Bringing a new medicine from idea to people’s medicine cabinets is like running an obstacle course. Yes, having solid science behind it is crucial, but that’s just the beginning. The American healthcare system has its quirks. Insurers need to give a nod, hospitals need to adapt to new methods, and doctors need to be convinced.

This process costs a lot of money—hundreds of millions, even a billion dollars—after all the scientific tests are done.

When you come across a small company that’s shown promising results in phase 2 or even phase 3 trials for a new drug, it’s time to dig into the numbers and dive into their financials. Check their balance sheet and cash flow. If financial jargon isn’t your strong suit, focus on a crucial question: “How fast are they spending their cash each quarter?” For instance, if they’re burning around $25 million per quarter and they only have $75 million left in the bank, alarm bells should ring.

Despite good results, a lack of funds could lead their breakthrough drug to end up in the trash bin. Smart financial moves are essential for turning promising data into real-world medical solutions.

This is where M&A steps in. Big pharma companies, with their knack for navigating red tape, join forces with agile biotech firms. M&A acts like a connector, ensuring innovative medicines actually reach the people who need them.

3. Key Shareholder: End of Career or Fresh Start?”

In the world of biotech, M&A isn’t just business—it’s about people and their journeys. Some founders, after years of battling the unpredictable industry, choose acquisition to secure their life’s work. On the flip side, young, ambitious founders, full of ideas, might be tempted by big corporations promising vast resources.

It’s not uncommon for a biotech company with a promising phase two product and solid data to command a valuation as high as $500 million. At this stage, the founding team has likely toiled in relative obscurity for years and looked to investors to fund their ambitious biotech endeavors.

Retaining majority control as a founder throughout product development is rare due to exorbitant costs. But the founder, or founding group, could retain around 5 to 10% of the company’s shares, possibly making them the largest and most influential shareholders. Hence, if Pfizer proposes to acquire the company for $500 million, that’s $50 million for the 67 year old scientist founder, who might just be tempted to take the giant payout and move to Bora Bora.

Another scenario involves young, inexperienced scientist-founders. This may seem counterintuitive; shouldn’t youth embody boldness?

Sometimes, these founders insist on going all the way. Yet, their inexperience can make them vulnerable to sophisticated corporate pitches. They’re promised abundant resources, a worry-free life, and a chance to change the world by teaming up with a giant like Pfizer.

Despite the allure, merging with massive corporations often stifles once-independent entrepreneurs. Ask anyone who’s sold their company to a corporate behemoth – it often isn’t conducive to the flourishing of once-autonomous entrepreneur.

Conclusion:

These tips can be crucial in spotting potential biotech takeovers, but there are still other factors to consider when piecing everything together. Even then, there’s no guarantee of a surefire deal. But if you  make smart, educated guesses with thorough research, you can reap substantial returns – a little luck doesn’t hurt either.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Aymanejed from Pixabay

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.